Abstract
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13048-021-00785-1.
Highlights
Hong Zhao1*, Rong Li1, Xiaoyan Wang2, Xin Lu1, Min Hu1, Jinbin Zhang2, Xia Zhao3, Xiaoqin Song4 and Yangyang Liu4
Retraction Note: The role of apatinib combined with paclitaxel in platinum-resistant ovarian cancer
The Editors-in-Chief have concluded that the data reported in this article are unreliable
Summary
Hong Zhao1* , Rong Li1, Xiaoyan Wang2, Xin Lu1, Min Hu1, Jinbin Zhang2, Xia Zhao3, Xiaoqin Song4 and Yangyang Liu4. Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer The Editors-in-Chief have retracted this article [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
